Serina Therapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Serina Therapeutics, Inc. (SER) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $424.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-29.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2022-03-29
- Serina Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2020-12-31 was $108.00K.
- Serina Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2020-09-30 was $107.00K.
- Serina Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2020 was $424.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2020-12-31 | $108.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $215.00K derived: sum of 2 quarters · filed 2022-03-29 | $424.00K 10-K · filed 2022-03-29 | |
| 2020-09-30 | $107.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $316.00K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $209.00K 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |